Lipids & metabolic liver disease
Metabolic dysfunction‐associated steatotic liver disease and cancer risk: A cohort study
Authors' conclusion
All subcategories of SLD, particularly MASLD with multiple metabolic abnormalities, were associated with increased risks of multiple cancers, providing a new perspective for cancer prevention.
Study context
- Population
- UK Biobank participants categorized by cardiometabolic factors, alcohol consumption and SLD aetiologyUK Biobank
- Participants
- 283,238 participants
- Exposure
- SLD subcategories vs no SLD
- No SLDn = 170,885reference
- MASLDn = 74,510
- MetALDn = 23,320
- Other SLDn = 6,718
- Outcome
- Overall incident cancer and 21 site-specific cancers
Methodological detailspopulation-based, UK Biobank
- Population-based
- UK Biobank
Main finding
As reported in the abstract
Overall cancer, digestive system cancers (except gastric) and breast cancer
All SLD subcategories associated with elevated risks of overall cancer, digestive system cancers (except gastric cancer) and breast cancer (HRs)
1.079-4.663
Overall incident cancer cases
39 352
Observational data: associations, not effects.
Further findings
Other site-specific cancers with MASLD
- MASLD associated with increased risks of renal cancer, endometrial cancer and Hodgkin lymphoma
Population attributable risk (PAR%)
- MASLD had a higher PAR% than MetALD and other SLDs for the majority of these cancers, largely explained by metabolic abnormalities (mainly overweight/obesity and elevated blood pressure, with hyperglycaemia and hyperlipidaemia)
Original publication
Metabolic dysfunction‐associated steatotic liver disease and cancer risk: A cohort study. Diabetes Obes Metab. Published 9 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →